NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis $1.30 0.00 (0.00%) (As of 11:29 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About NextCure Stock (NASDAQ:NXTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NextCure alerts:Sign Up Key Stats Today's Range$1.30▼$1.3350-Day Range$1.27▼$1.5452-Week Range$1.03▼$2.57Volume24,297 shsAverage Volume120,072 shsMarket Capitalization$36.41 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! NextCure Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreNXTC MarketRank™: NextCure scored higher than 88% of companies evaluated by MarketBeat, and ranked 87th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNextCure has only been the subject of 1 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NextCure's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 10.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.79 Percentage of Shares Shorted0.31% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 10.43%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NextCure this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NXTC Stock News HeadlinesPreclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNovember 19 at 8:05 AM | globenewswire.comNextCure Reports Improved Financial Performance and Strategic FocusNovember 12, 2024 | markets.businessinsider.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)NextCure’s Strategic Shift and Financial Stability Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comNextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comNextCure reports data from LNCB74, NC410 studiesNovember 7, 2024 | markets.businessinsider.comNextCure (NXTC) Earnings Dates & ReportsNovember 5, 2024 | investing.comNextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNovember 5, 2024 | globenewswire.comSee More Headlines NXTC Stock Analysis - Frequently Asked Questions How have NXTC shares performed this year? NextCure's stock was trading at $1.14 at the beginning of 2024. Since then, NXTC stock has increased by 14.0% and is now trading at $1.30. View the best growth stocks for 2024 here. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) announced its quarterly earnings data on Thursday, August, 1st. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.19. When did NextCure IPO? NextCure (NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO. Who are NextCure's major shareholders? Top institutional investors of NextCure include Geode Capital Management LLC (0.80%) and Assenagon Asset Management S.A. (0.30%). View institutional ownership trends. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/01/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NXTC CUSIPN/A CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees90Year Founded2015Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+207.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.50% Return on Assets-53.67% Debt Debt-to-Equity RatioN/A Current Ratio9.07 Quick Ratio9.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.32Miscellaneous Outstanding Shares28,007,000Free Float24,282,000Market Cap$36.41 million OptionableOptionable Beta0.80 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:NXTC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.